Zhang Chunyan, Lou Jingwei, Li Nainong, Todorov Ivan, Lin Chia-Lei, Cao Yu-An, Contag Christopher H, Kandeel Fouad, Forman Stephen, Zeng Defu
Beckman Research Institute, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
J Immunol. 2007 Jan 15;178(2):838-50. doi: 10.4049/jimmunol.178.2.838.
Donor CD8(+) T cells play a critical role in mediating graft-vs-leukemia (GVL) activity, but also induce graft-vs-host disease (GVHD) in recipients conditioned with total body irradiation (TBI). In this study, we report that injections of donor C57BL/6 (H-2(b)) or FVB/N (H-2(q)) CD8(+) T with bone marrow cells induced chimerism and eliminated BCL1 leukemia/lymphoma cells without clinical signs of GVHD in anti-CD3-conditioned BALB/c (H-2(d)) recipients, but induced lethal GVHD in TBI-conditioned recipients. Using in vivo and ex vivo bioluminescent imaging, we observed that donor CD8(+) T cells expanded rapidly and infiltrated GVHD target tissues in TBI-conditioned recipients, but donor CD8(+) T cell expansion in anti-CD3-conditioned recipients was confined to lymphohematological tissues. This confinement was associated with lack of up-regulated expression of alpha(4)beta(7) integrin and chemokine receptors (i.e., CXCR3) on donor CD8(+) T cells. In addition, donor CD8(+) T cells in anti-CD3-conditioned recipients were rendered unresponsive, anergic, Foxp3(+), or type II cytotoxic T phenotype. Those donor CD8(+) T cells showed strong suppressive activity in vitro and mediated GVL activity without clinical signs of GVHD in TBI-conditioned secondary recipients. These results indicate that anti-CD3 conditioning separates GVL activity from GVHD via confining donor CD8(+) T cell expansion to host lymphohemological tissues as well as tolerizing them in the host.
供体CD8(+) T细胞在介导移植物抗白血病(GVL)活性中发挥关键作用,但在接受全身照射(TBI)预处理的受者中也会诱发移植物抗宿主病(GVHD)。在本研究中,我们报告,在抗CD3预处理的BALB/c(H-2(d))受者中,注射供体C57BL/6(H-2(b))或FVB/N(H-2(q))CD8(+) T细胞与骨髓细胞可诱导嵌合体形成并消除BCL1白血病/淋巴瘤细胞,且无GVHD的临床症状,但在TBI预处理的受者中会诱发致死性GVHD。利用体内和体外生物发光成像,我们观察到在TBI预处理的受者中,供体CD8(+) T细胞迅速扩增并浸润GVHD靶组织,但在抗CD3预处理的受者中,供体CD8(+) T细胞的扩增局限于淋巴造血组织。这种局限与供体CD8(+) T细胞上α(4)β(7)整合素和趋化因子受体(即CXCR3)表达上调的缺失有关。此外,在抗CD3预处理的受者中,供体CD8(+) T细胞变得无反应、无活性、Foxp3(+)或呈II型细胞毒性T表型。那些供体CD8(+) T细胞在体外表现出强大的抑制活性,并在TBI预处理的二级受者中介导GVL活性,而无GVHD的临床症状。这些结果表明,抗CD3预处理通过将供体CD8(+) T细胞的扩增限制在宿主淋巴造血组织以及使它们在宿主体内产生耐受性,从而将GVL活性与GVHD分离。